EyeGate Pharma : Press 2013

EyeGate Pharma

Press Releases

2013

04/09/13
EyeGate's EGP-437 Matches the Standard-of-Care's Response Rate in Phase III Study of Patients with Anterior Uveitis.

2012

12/18/2012
EyeGate Enrolls Last Patient in Pivotal Phase III Anterior Uveitis Study of EGP-437

10/25/2012
Avedro and EyeGate Pharma Enter Agreement for Corneal Cross-linking IP

3/1/2012
EyeGate Pharma Initiates Phase I Study of EGP-437 in Patients with Non-necrotizing Anterior Scleritis

1/5/2012
EyeGate Pharma initiates Phase III Study of EGP-437 in Patients with Anterior Uveitis